Drug Hypersensitivity Clinical Trial
Official title:
Clinical Evaluation of Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase, 150 USP Units/mL) Open Label, Normal Volunteer Study
Verified date | March 2013 |
Source | Bausch & Lomb Incorporated |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The objective of this study was to rule out a greater than 10% incidence of hypersensitivity to Vitrase following a single intradermal injection of 3 USP units Vitrase. Less than or equal to a 10% hypersensitivity response was considered acceptable.
Status | Completed |
Enrollment | 65 |
Est. completion date | September 2004 |
Est. primary completion date | July 2004 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Agreed to avoid disallowed meds Exclusion Criteria: - Known hypersensitivity to hyaluronidase and/or bee sting - Previous known exposure to ovine hyaluronidase or bovine hyaluronidase - Atopic individuals assessed by medical history - Topical/inhaled/systemic corticosteroids within 30 days - Concurrent use of antihistamines or anti-inflammatory during study - Active or chronic disease likely to affect immune function - History of alcohol/drug abuse within 6 months |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label
Country | Name | City | State |
---|---|---|---|
United States | Solano Clinical Research (A Division of Dow Pharmaceutical Sciences) | Davis | California |
Lead Sponsor | Collaborator |
---|---|
Bausch & Lomb Incorporated |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hypersensitivity | Incidence of hypersensitivity to Vitrase following a single intradermal injection of 4.5 USP units Vitrase. | 1-2 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02839551 -
Optimal Doses for Drug Provocation Tests to Beta-lactams
|
N/A | |
Completed |
NCT00198419 -
Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)
|
Phase 1 | |
Completed |
NCT02839811 -
Medical Device for Drug Allergy Diagnosis
|
N/A | |
Completed |
NCT02983630 -
Allergy Testing of Patients Labeled as Penicillin Allergic
|
N/A | |
Recruiting |
NCT04330118 -
Origin and Function of Eosinophilic Polynuclear During DRESS Syndrome
|
||
Completed |
NCT04421638 -
Cephalosporin Hypersensitivity
|
||
Recruiting |
NCT02031120 -
Management of Drug Hypersensitivity in Children
|
N/A | |
Completed |
NCT01276314 -
Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions
|
N/A | |
Terminated |
NCT00505648 -
Treatment of Hypersensitivity Syndrome (DRESS) With Tegeline® (Human Immunoglobulin)
|
Phase 3 | |
Completed |
NCT03158831 -
Drug Challenges Without Prior Skin Testing
|
Phase 1 | |
Completed |
NCT03076749 -
Predictive Models for Betalactam Allergy
|
N/A | |
Active, not recruiting |
NCT06428162 -
An Evaluation of Healthcare Providers' Adherence to Pharmacovigilance Practices in an African Community
|
||
Terminated |
NCT02844712 -
Negative Predictive Value of Drug Provocation Tests to Beta-lactams
|
N/A | |
Completed |
NCT03771118 -
Drug Provocation Test (DPT) to Paracetamol
|
||
Completed |
NCT03743220 -
Drug Provocation Test (DPT) to Non Steroidal Anti-inflammatory Drugs (NSAID)
|
||
Not yet recruiting |
NCT06406114 -
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
|
Phase 2 | |
Completed |
NCT05269082 -
A Study to Assess the Hypersensitivity to TAK-880 Compared to Gammagard S/D in Blood of Children, Teenagers and Adults
|
||
Completed |
NCT04827602 -
Drug Allergy Labels After Drug Allergy Investigation
|